(Q36643703)

15 August 2017

title

Treatment outcome for metastatic papillary renal cell carcinoma patients (English)

1 reference

15 August 2017

1 reference

8

Robert J Motzer

1 reference

15 August 2017

Ellen A Ronnen

1

1 reference

15 August 2017

G Varuni Kondagunta

2

1 reference

15 August 2017

Nicole Ishill

3

1 reference

15 August 2017

Lesley Spodek

4

1 reference

15 August 2017

Paul Russo

5

1 reference

15 August 2017

Victor Reuter

6

1 reference

15 August 2017

Jennifer Bacik

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

107

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

2617-2621

1 reference

Adult renal epithelial neoplasms

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

Therapeutic options for variant renal cancer: a true orphan disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22340

1 reference

7 January 2021

Specific chromosome aberration in human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

The impact of genetics on the classification of renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Cytogenetic classification of renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

The genetic basis of cancer of the kidney

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

A molecular classification of papillary renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22340

7 January 2021

Identifiers

DOI

10.1002/CNCR.22340

1 reference

15 August 2017

1 reference